Utah Retirement Systems increased its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 0.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,903 shares of the biopharmaceutical company’s stock after buying an additional 200 shares during the period. Utah Retirement Systems’ holdings in Alexion Pharmaceuticals were worth $4,855,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Guardian Life Insurance Co. of America raised its position in Alexion Pharmaceuticals by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 6 shares during the last quarter. Eqis Capital Management Inc. raised its position in Alexion Pharmaceuticals by 0.6% in the second quarter. Eqis Capital Management Inc. now owns 6,776 shares of the biopharmaceutical company’s stock worth $824,000 after buying an additional 38 shares during the last quarter. Cleararc Capital Inc. raised its position in Alexion Pharmaceuticals by 1.0% in the first quarter. Cleararc Capital Inc. now owns 5,495 shares of the biopharmaceutical company’s stock worth $666,000 after buying an additional 53 shares during the last quarter. Seven Bridges Advisors LLC raised its stake in Alexion Pharmaceuticals by 2.1% in the second quarter. Seven Bridges Advisors LLC now owns 2,638 shares of the biopharmaceutical company’s stock valued at $321,000 after buying an additional 53 shares in the last quarter. Finally, Geneva Advisors LLC raised its stake in Alexion Pharmaceuticals by 0.7% in the second quarter. Geneva Advisors LLC now owns 11,408 shares of the biopharmaceutical company’s stock valued at $1,388,000 after buying an additional 82 shares in the last quarter. 94.26% of the stock is owned by hedge funds and other institutional investors.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at 137.54 on Monday. The firm’s 50 day moving average price is $132.60 and its 200-day moving average price is $123.39. The stock has a market cap of $30.70 billion, a P/E ratio of 59.64 and a beta of 1.41. Alexion Pharmaceuticals, Inc. has a 12-month low of $96.18 and a 12-month high of $145.41.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, beating the Zacks’ consensus estimate of $1.08 by $0.48. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The company had revenue of $912 million for the quarter, compared to the consensus estimate of $846.15 million. During the same period in the prior year, the firm posted $1.13 EPS. The company’s quarterly revenue was up 21.1% compared to the same quarter last year. Equities research analysts anticipate that Alexion Pharmaceuticals, Inc. will post $5.60 earnings per share for the current fiscal year.

WARNING: This piece was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another site, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/28/utah-retirement-systems-has-4-86-million-stake-in-alexion-pharmaceuticals-inc-alxn.html.

Several equities research analysts recently issued reports on the company. UBS AG reissued a “buy” rating and set a $140.00 price objective (down previously from $143.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, May 31st. BidaskClub lowered Alexion Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, August 14th. Evercore ISI assumed coverage on Alexion Pharmaceuticals in a research note on Wednesday, August 16th. They set an “in-line” rating and a $137.00 price objective for the company. Zacks Investment Research raised Alexion Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $158.00 price objective for the company in a research note on Wednesday, August 2nd. Finally, Jefferies Group LLC set a $120.00 price objective on Alexion Pharmaceuticals and gave the company a “hold” rating in a research note on Thursday, June 8th. Six analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $156.13.

In other news, CEO Ludwig Hantson acquired 10,000 shares of the company’s stock in a transaction on Wednesday, June 14th. The shares were bought at an average cost of $116.72 per share, with a total value of $1,167,200.00. Following the transaction, the chief executive officer now owns 38,725 shares in the company, valued at approximately $4,519,982. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Ann M. Veneman sold 700 shares of the stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $137.74, for a total transaction of $96,418.00. Following the completion of the sale, the director now directly owns 6,315 shares in the company, valued at $869,828.10. The disclosure for this sale can be found here. Over the last three months, insiders acquired 2,019,734 shares of company stock worth $235,606,846. Insiders own 4.35% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.